Acalabrutinib monotherapy as a first-line treatment for CLL: 3-year follow-up of the real-world EPIC study.

Eyre TA, Martinez-Calle N, Paneesha S, Norouzi M, Tucker D, Walter H, Boden A, Kilner M, Phillips N, Patten PEM, Shah N, Ruparelia M, Oddy S, Tsawayo T, Forconi F, Wardle H, Gbemre T, Gregory C, Cook L, Allsup D, Morris A, Knechtli C, Davies J, Galani J, Marr H, Hutchinson C, Williams S, Hickey J, Harding H, Hunjan S, Blak BT, Walewska R

Open source

DOI: 10.1182/bloodadvances.2026019978
Published: 2026 Jul 28
Container: Blood advances
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1182/bloodadvances.2026019978,
  title = {Acalabrutinib monotherapy as a first-line treatment for CLL: 3-year follow-up of the real-world EPIC study.},
  author = {Eyre TA and Martinez-Calle N and Paneesha S and Norouzi M and Tucker D and Walter H and Boden A and Kilner M and Phillips N and Patten PEM and Shah N and Ruparelia M and Oddy S and Tsawayo T and Forconi F and Wardle H and Gbemre T and Gregory C and Cook L and Allsup D and Morris A and Knechtli C and Davies J and Galani J and Marr H and Hutchinson C and Williams S and Hickey J and Harding H and Hunjan S and Blak BT and Walewska R},
  year = {2026},
  journal = {Blood advances},
  doi = {10.1182/bloodadvances.2026019978},
  url = {https://doi.org/10.1182/bloodadvances.2026019978}
}

RIS

TY  - JOUR
TI  - Acalabrutinib monotherapy as a first-line treatment for CLL: 3-year follow-up of the real-world EPIC study.
AU  - Eyre TA
AU  - Martinez-Calle N
AU  - Paneesha S
AU  - Norouzi M
AU  - Tucker D
AU  - Walter H
AU  - Boden A
AU  - Kilner M
AU  - Phillips N
AU  - Patten PEM
AU  - Shah N
AU  - Ruparelia M
AU  - Oddy S
AU  - Tsawayo T
AU  - Forconi F
AU  - Wardle H
AU  - Gbemre T
AU  - Gregory C
AU  - Cook L
AU  - Allsup D
AU  - Morris A
AU  - Knechtli C
AU  - Davies J
AU  - Galani J
AU  - Marr H
AU  - Hutchinson C
AU  - Williams S
AU  - Hickey J
AU  - Harding H
AU  - Hunjan S
AU  - Blak BT
AU  - Walewska R
PY  - 2026
JO  - Blood advances
DO  - 10.1182/bloodadvances.2026019978
UR  - https://doi.org/10.1182/bloodadvances.2026019978
ER  -

APA

TA, E., N, M., S, P., M, N., D, T., H, W., A, B., M, K., N, P., PEM, P., N, S., M, R., S, O., T, T., F, F., H, W., T, G., C, G., L, C., D, A., A, M., C, K., J, D., J, G., H, M., C, H., S, W., J, H., H, H., S, H., BT, B., & R, W. (2026). Acalabrutinib monotherapy as a first-line treatment for CLL: 3-year follow-up of the real-world EPIC study.. Blood advances. https://doi.org/10.1182/bloodadvances.2026019978

Source records

pubmed · retrieved 2026-09-26T13:16:53.372Z